Ischemic Stroke clinical trials at UC Davis

3 in progress, 1 open to eligible people

Showing trials for

  • Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

    open to eligible people ages 22-85

    REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

    Sacramento, California and other locations

  • Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

    Sacramento, California and other locations

  • Sleep for Stroke Management and Recovery Trial

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.

    Sacramento, California and other locations

Our lead scientists for Ischemic Stroke research studies include .

Last updated: